Personal view: To treat or not to treat? Helicobacter pylori and gastro-oesophageal reflux disease - An alternative hypothesis

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 3, 2004, Pages 253-261

  Axon, A T R ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DISEASE ASSOCIATION; DYSPEPSIA; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION;

GASTRIC ACID; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 1342289050     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01847.x     Document Type: Review

References (78)

1. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000; 321: 659-64.
2. Blaser MJ. Science, medicine, and the future - Helicobacter pylori and gastric diseases. Br Med J 1998; 316: 1507-10.
3. Blaser MJ. Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. Gut 1998; 43: 721-7.
4. Bytzer P, Christensen PP, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 86-91.
5. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
6. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55: 2111-5.
7. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-33.
8. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 1998; 93: 1800-2.
9. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
10. + H. pylori in GERD and Barrett's esophagus (BE) with or without dysplasia or adenocarcinoma (D/AC): a meta-analysis. Gastroenterology 2002; 122: A291(Abstract).
11. Raghunath A, Hungin APS, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. Br Med J 2003; 326: 737-9.
12. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
13. Loffeld RJLF, Werdmuller BFM, Kuster JG, Perez-Perez GI, Blaser MJ, Kuipers EJ. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000; 62: 95-9.
14. + Helicobacter pylori in reflux oesophagitis. Gut 2001; 49: 341-6.
15. Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000; 95: 2206-11.
16. Malfertheiner P, Dent J, Zeijlon L, et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Aliment Pharmacol Ther 2002; 16: 1431-42.
17. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 45-51.
18. Befrits R, Sjostedt S, Odman B, Sorngard H, Lindberg G. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter 2000; 5: 202-5.
19. McColl KEL, Dickson A, El-Nujumi A, El-Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 101-5.
20. Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14: 729-35.
21. Nakajima S, Hattori T. Active and inactive gastroesophageal reflux disease related to Helicobacter pylori therapy. Helicobacter 2003; 8: 279-93.
22. Calam J. Helicobacter pylori modulation of gastric acid. Yale J Biol Med 1999; 72: 195-202.
23. Harris AW, Gummett PA, Misiewicz JJ, Baron JH. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs in response to gastrin releasing peptide and pentagastrin. Gut 1996; 38: 663-7.
24. McColl KEL, El-Omar E, Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am 2000; 29: 687-703.
25. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon ATR. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-6.
26. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001; 357: 1738-42.
27. Tefera S, Hatlebakk JG, Berstad AE, Berstad A. Eradication of Helicobacter pylori does not increase acid reflux in patients with mild to moderate reflux oesophagitis. Scand J Gastroenterol 2002; 37: 877-83.
28. Wildner-Christensen M, Hansen JM, Schaffalitzky de Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003; 125: 372-9.
29. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet 2000; 355: 1665-9.
30. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49: 330-4.
31. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 1997; 41: 452-8.
32. Baron JH. Lean body mass, gastric acid and peptic ulcer. Gut 1969; 10: 637-42.
33. Hume R, Melrose AG. Relation between maximal acid output of stomach and lean body mass. Br Med J 1967; 2: 30-1.
34. Elder JB, Smith IS. Gastric-acid output, pepsin output, and lean body mass in normal and duodenal ulcer subjects. Lancet 1975; 1: 1000-3.
35. Hauspie RC, Vercauteren M, Susanne C. Secular changes in growth. Horm Res 1996; 45(Suppl. 2): 8-17.
36. Cole TJ. Secular trends in growth. Proc Nutrition Soc 2000; 59: 317-24.
37. Kuh DK, Power C, Rodgers B. Secular trends in social class and sex differences in adult height. Int J Epidemiol 1991; 20: 1001-9.
38. Mendall MA, Molineaux N, Levi J, Strachan D, Northfield TC. Association of H. pylori with diminished adult height. Gut 1994; 35: S4.
39. Patel P, Mendall MA, Khulusi S, Northfield TC, Strachan DP. Helicobacter pylori infection in childhood: risk factors and effect on growth. Br Med J 1994; 309: 1119-23.
40. Passaro DJ, Taylor DN, Gilman RH, Cabrera L, Parsonnet J. Growth slowing after acute Helicobacter pylori infection is age-dependent. J Pediatr Gastroenterol Nutr 2002; 35: 522-6.
41. Richter T, List S, Muller DM, et al. Five to seven year old children with Helicobacter pylori infection are smaller than Helicobacter-negative children: a cross-sectional population-based study of 3.315 children. J Pediatr Gastroenterol Nutr 2001; 33: 472-5.
42. Perri F, Pastore M, Leandro G, et al. Helicobacter pylori infection and growth delay in older children. Arch Dis Child 1997; 77: 46-9.
43. Smith GD, Hart C, Upton M, et al. Height and risk of death among men and women: aetiological implications of associations with cardiorespiratory disease and cancer mortality. J Epidemiol Community Health 2000; 54: 97-103.
44. Lee A, Mellgard B, Larsson H. Effect of gastric acid on Helicobacter pylori ecology. In: Hunt RH, Tytgat GNJ, eds. Helicobacter Pylori Basic Mechanisms to Clinical Cure 1996. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1996: 50-63.
45. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Helicobacter pylori and the gastric environment. In: Hunt RH, Tytgat GNJ, eds. Helicobacter Pylori Basic Mechanisms to Clinical Cure 1996. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1996: 64-77.
46. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997; 41: 740-7.
47. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
48. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5: 206-14.
49. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205-13.
50. Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 247-53.
51. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90: 1401-6.
52. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
53. Solcia E, Villani L, Fiocca R, et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994; 29(Suppl. 201): 28-34.
54. 2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 729-34.
55. Suzuki M, Suzuki H, Kitahora T, et al. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis. Aliment Pharmacol Ther 2002; 16: 159-65.
56. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 615-21.
57. Deren JS. Development of structure and function in the fetal and newborn stomach. Am J Clin Nutr 1971; 24: 144-59.
58. Calam J, Beales ILP, Gibbons A, Ghatei M, Del Valle J. Effects of abnormalities of gastrin and somatostatin in Helicobacter pylori infection on acid secretion. In: Hunt RH, Tytgat GNJ, eds. Helicobacter Pylori Basic Mechanisms to Clinical Cure 1996. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1996: 108-21.
59. El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-91.
60. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993; 34: 888-92.
61. Harris AW, Gummett PA, Misiewicz JJ, Baron JH. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Gut 1996; 38: 663-7.
62. Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340: 930-2.
63. Feldman M, Cryer B, Sammer D, Lee E, Spechler SJ. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. Am J Physiol 1999; 277: 1159-64.
64. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
65. Gutierrez O, Melo M, Segura AM, Angel A, Genta RM, Graham DY. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32: 664-8.
66. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
67. DeLuca VA, West B, Haque S, et al. Long-term symptom patterns, endoscopic findings, and gastric histology in Helicobacter pylori-infected and uninfected patients. J Clin Gastroenterol 1998; 26: 106-12.
68. Marshall BJ, Warren JR. Unidentified curved bacillus on gastric epithelium in active chronic gastritis. Lancet 1983; i: 1273-5.
69. Richter JE. H. pylori: the bug is not all bad. Gut 2001; 49: 319-21.
70. Haruma K, Hamada H, Mihara M, et al. Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: case-control study in Japan. Helicobacter 2000; 5: 24-9.
71. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999; 94: 3468-72.
72. El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux oesophagitis. Gut 1999; 45: 181-5.
73. Gillen D, Wirz AA, Neithercut WD, et al. Helicobacter pylori infection potentiates the Inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 468-75.
74. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-13.
75. Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. Br Med J 1999; 319: 550-3.
76. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-6.
77. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
78. Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16: 1449-56.